期刊
JOURNAL OF IMMUNOLOGY
卷 181, 期 4, 页码 2563-2571出版社
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.181.4.2563
关键词
-
类别
资金
- NCI NIH HHS [R37 CA025000, R01 CA025000, CA-25000, R01 CA025000-30] Funding Source: Medline
Analogous to the clinical use of recombinant high-affinity Abs, transfer of TCR genes may be used to create a T cell compartment specific for self-Ags to which the endogenous T cell repertoire is immune tolerant. In this study, we show in a spontaneous prostate carcinoma model that the combination of vaccination with adoptive transfer of small numbers of T cells that are genetically modified with a tumor-specific TCR results in a marked suppression of tumor development, even though both treatments are by themselves without effect. These results demonstrate the value of TCR gene transfer to target otherwise nonimmunogenic tumor-associated self-Ags provided that adoptive transfer occurs under conditions that allow in vivo expansion of the TCR-modified T cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据